Latest Replimune News & Updates

See the latest news and media coverage for Replimune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Replimune

Commercial-stage biotechnology company developing oncolytic cancer immunotherapies

replimune.com

Headquarters: Woburn, United States
Founded year: 2015
Company type: Public company
Number of employees: 340–500
Industry: Biotechnology & Medical Research

Last updated Yesterday

Latest news about Replimune

In short: Replimune launched TUDRIQEV after FDA approval and reported $307.8 million in cash

Company announcements

October 28 Replimune

Replimune reports Q2 2027 financial results and commercial update

Cash stands at $307.8 million following equity proceeds. TUDRIQEV launches for melanoma, while R&D expenses drop to $34.4 million amid clinical trial advancements.

October 1 Replimune

Replimune launches TUDRIQEV in the U.S

The oncolytic therapy is now available for advanced melanoma patients with next-day delivery and support services. It received accelerated FDA approval based on trial response rates.

August 14 Replimune

Replimune reports fiscal Q1 2027 results and TUDRIQEV approval

The FDA granted accelerated approval for TUDRIQEV with nivolumab for advanced melanoma. The company expects launch within 60 days, completed a $150 million financing, and appointed a new Chief Commercial Officer.

August 10 Replimune

Replimune announces pricing of $150 million underwritten offering

The offering includes 9,701,490 shares and pre-funded warrants for 2,736,340 shares, with gross proceeds of approximately $150 million before expenses.

Media coverage

Yesterday Yahoo Finance

How Investors May Respond To Replimune Group (REPL) Narrower Quarterly Loss

Replimune Group reported second quarter 2026 results with a net loss of US$57.12 million and basic loss per share of US$0.54, ...

October 28 Seeking Alpha

Replimune Group GAAP EPS of -$0.54 beats by $0.21 (REPL:NASDAQ)

Replimune Q2 earnings beat estimates, with cash rising to $307.8M and R&D costs falling.

October 21 BioSpace

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update - BioSpace

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic...

October 16 GuruFocus

Replimune Group (REPL) Launches TUDRIQEV with Early Adoption Ami

On October 28, 2026, Replimune Group Inc (NASDAQ: REPL) announced the commercial launch of its first...

Never miss news about Replimune

Track Replimune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Replimune competitors & trending companies

Browse news for competitors to Replimune and other trending companies.